99059-83-3

Usage

Uses

Used in Recreational Settings:
1-Benzofuran-2-yl-ethylamine is used as a recreational drug for its hallucinogenic effects, often taken orally in social settings. It is known to induce feelings of empathy and euphoria, making it a popular choice for those seeking altered states of consciousness.
Used in Therapeutic Research:
1-Benzofuran-2-yl-ethylamine is used as a subject of research for its potential therapeutic applications. Studies have explored its use in the treatment of post-traumatic stress disorder and social anxiety, although further research is needed to fully understand its efficacy and safety in such contexts.

InChI:InChI=1/C10H11NO/c1-7(11)10-6-8-4-2-3-5-9(8)12-10/h2-7H,11H2,1H3/p+1/t7-/m1/s1

Upstream product

• 1646-26-0 1-(benzo[b]furan-2-yl)ethanone 
• 77287-34-4 formamide 
• 91880-85-2 1-(benzofuran-2-yl)ethan-1-one oxime 
• 119619-37-3 1-(benzofuran-2-yl)ethan-1-ol 

Downstream Products

• 1212877-42-3 (R)-1-(benzofuran-2-yl)ethylamine 
• 939792-89-9 (S)-1-(benzofuran-2-yl)ethanamine 
• 1392234-16-0 C₁₄H₁₇NO₂ 

Relevant academic research and scientific papers

Virtual Screening Approach to Identifying a Novel and Tractable Series of Pseudomonas aeruginosa Elastase Inhibitors

Novel therapies are required to treat chronic bacterial infections in cystic fibrosis (CF) sufferers. The most common pathogen responsible for these infections is Pseudomonas aeruginosa, which persists within the lungs of CF sufferers despite intensive antibiotic treatment. P. aeruginosa elastase (also known as LasB or pseudolysin) is a key virulence determinant that contributes to the pathogenesis and persistence of P. aeruginosa infections in CF patients. The crucial role of LasB in pseudomonal virulence makes it a good target for the development of an adjuvant drug for CF treatment. Herein we discuss the discovery of a new series of LasB inhibitors by virtual screening and computer assisted drug design (CADD) and their optimization leading to compounds 29 and 39 (Ki = 0.16 μM and 0.12 μM, respectively).

CATALYST COMPOUNDS

The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.

Primary amines by transfer hydrogenative reductive amination of ketones by using cyclometalated IrIII catalysts

Cyclometalated iridium complexes are found to be versatile catalysts for the direct reductive amination (DRA) of carbonyls to give primary amines under transfer-hydrogenation conditions with ammonium formate as both the nitrogen and hydrogen source. These complexes are easy to synthesise and their ligands can be easily tuned. The activity and chemoselectivity of the catalyst towards primary amines is excellent, with a substrate to catalyst ratio (S/C) of 1000 being feasible. Both aromatic and aliphatic primary amines were obtained in high yields. Moreover, a first example of homogeneously catalysed transfer-hydrogenative DRA has been realised for β-keto ethers, leading to the corresponding β-amino ethers. In addition, non-natural α-amino acids could also be obtained in excellent yields with this method. Reduce the work! A broad range of ketones have been successfully aminated to afford primary amines under transfer-hydrogenation conditions by using ammonium formate as the amine source and 0.1 mol % of a cyclometalated IrIII catalyst (see scheme). Copyright

CATALYST COMPOUNDS

The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions.

Chemoenzymatic preparation of 1-heteroarylethanamines of low solubility

Both enantiomers of biologically and pharmaceutically interesting benzofuran-, benzothiophen-, and phenylfuran-based 1-heteroarylethanamines were prepared at close to theoretical yields by using Candida antarctica lipase B (Novozym 435) catalyzed (R)-selective N-acylation with isopropyl butanoate (enantiomeric ratio E > 200). The use of N-methyl-2-pyrrolidinone (NMP) as a cosolvent (1:30) in isopropyl butanoate solved the problem of low solubility of the compounds. Instability of the heterocyclic ring systems against traditional acid- and base-catalyzed hydrolysis was solved by using Candida antarctica lipase A as a commercial CAL-A-CLEA preparation for deprotection of the N-acylated (R) enantiomers in water. The slow, highly enantioselective (E > 200) hydrolyses of racemic butanamides was also observed in the presence of Novozym 435. Copyright

Triazine derivatives, and herbicides containing the derivatives as the effective component

A triazine derivative represented by the general formula: STR1 or the general formula: STR2 (wherein X1 represents a hydrogen atom, a halogen atom an alkyl group having 1 to 4 carbon atoms or an alkoxyl group having 1 to 4 carbon atoms, Z represents an oxygen atom or a sulfur atom, R1 represents an alkyl group having 1 to 4 carbon atom, and R2 represents a halogen atom, an alkylthio group having 1 to 4 carbon atoms, or an alkoxyl group having 1 to 4 carbon atoms). This invention also provides a process for efficiently preparing said triazine derivative and a herbicide containing said triazine derivative as a herbicidally effective component.